Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sanjay Sheth

Internal Medicine Niles, OH Medical Doctor

NPI 1285616383 CMS profile 285537

940 Robbins Ave, Niles, OH 44446

Open in the dashboard

General payments

$16,172

820 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sanjay Sheth of Niles, OH is reported in the CMS Open Payments database as having received $16,172 across 820 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,656 111
2024 General $2,789 123
2023 General $2,603 131
2022 General $2,605 127
2021 General $2,306 124
2020 General $1,224 81
2019 General $1,988 123

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sanjay Sheth
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Sanjay Sheth were reported at $2,656. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Sanjay Sheth Internal Medicine median Middle half National median
2019 $1,988 $159 $48–$570 $163
2020 $1,224 $119 $33–$402 $114
2021 $2,306 $135 $37–$521 $132
2022 $2,605 $141 $42–$496 $149
2023 $2,603 $149 $45–$519 $160
2024 $2,789 $154 $47–$537 $164
2025 $2,656 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,560 80 payments
  2. AbbVie, Inc. $2,162 109 payments
  3. Lilly USA, LLC $1,010 71 payments
  4. Pfizer Inc. $977 60 payments
  5. Novo Nordisk Inc $918 84 payments
  6. Merck Sharp & Dohme Corporation $905 51 payments
  7. GlaxoSmithKline, LLC. $890 46 payments
  8. Amgen Inc. $854 37 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $845 58 payments
  10. Amarin Pharma Inc. $647 47 payments
  11. Other $4,405 177 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,158 818 payments
  2. Education $14 2 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR $1,171 51 payments
  2. FARXIGA $1,109 27 payments
  3. BREZTRI $972 33 payments
  4. VERQUVO $849 45 payments
  5. AIRSUPRA $778 17 payments
  6. NURTEC ODT $700 20 payments
  7. Ozempic $688 66 payments
  8. UBRELVY $583 35 payments
  9. TRELEGY ELLIPTA $572 35 payments
  10. QULIPTA $529 32 payments
  11. Other $13,401 793 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 145 drugs

Part D claims

8,440

Median for Internal Medicine: 777

Drug cost

$1,104,075

Median for Internal Medicine: $73,373

Branded share of claims

27.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 129 $141,874
Jardiance Empagliflozin Brand 121 $129,867
Mounjaro Tirzepatide Brand 93 $107,464
Trulicity Dulaglutide Brand 64 $101,662
Farxiga Dapagliflozin Propanediol Brand 64 $57,707
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 62 $57,440
Ozempic Semaglutide Brand 37 $53,582
Entresto Sacubitril/Valsartan Brand 23 $39,394
Vascepa Icosapent Ethyl Brand 60 $37,868
Vraylar Cariprazine Hcl Brand 14 $35,891

The 10 drugs with the highest cost, of 145 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$106,656

Of which drugs: $9,191

Medicare patients

231

Average age 74

Services billed

1,654

126 women, 105 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 35%
Ischemic heart disease 33%
Depression 32%
Chronic kidney disease 29%
Atrial fibrillation 25%
Heart failure 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 24 24 $6,900
Influenza vaccine, trivalent derived from cell cultures 90661 Office 46 46 $1,661

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $393
$393 14 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $258
$258 — —
KRYSTEXXA
  • Amgen Inc. $214
$214 — —
AREXVY
  • GlaxoSmithKline, LLC. $163
$164 — —
JARDIANCE
  • Lilly USA, LLC $102
  • Boehringer Ingelheim Pharmaceuticals, Inc. $44
$147 121 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

820 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record